Your browser doesn't support javascript.
loading
Screening for Differences in Early Exposure in the Fasted State with in Vitro Methodologies can be Challenging: Experience with the BioGIT System.
Kostantini, Christina; Spilioti, Evanthia; Bevernage, Jan; Ceulemans, Jens; Hansmann, Simone; Hellemans, Katleen; Jede, Christian; Kourentas, Alexandros; Reggane, Maude; Shah, Lipa; Wagner, Christian; Vertzoni, Maria; Reppas, Christos.
Afiliación
  • Kostantini C; Department of Pharmacy, National and Kapodistrian University of Athens, Zografou, Greece.
  • Spilioti E; Department of Pharmacy, National and Kapodistrian University of Athens, Zografou, Greece.
  • Bevernage J; Janssen Pharmaceutica NV, Beerse, Belgium.
  • Ceulemans J; Janssen Pharmaceutica NV, Beerse, Belgium.
  • Hansmann S; Chemical & Pharmaceutical Development, Merck Healthcare KGaA, The healthcare business of Merck KGaA, Darmstadt, Germany.
  • Hellemans K; Janssen Pharmaceutica NV, Beerse, Belgium.
  • Jede C; Chemical & Pharmaceutical Development, Merck Healthcare KGaA, The healthcare business of Merck KGaA, Darmstadt, Germany.
  • Kourentas A; Dissolution & Biopharmaceutics, Analytical Research and Development, Technical Research and Development, Novartis AG, CH-4056, Basel, Switzerland.
  • Reggane M; Pharmaceutical Development, Technical Research and Development, Novartis AG, CH-4056, Basel, Switzerland.
  • Shah L; Pharmaceutical Development, Technical Research and Development, Novartis Pharmaceuticals Corporation, Fort Worth TX 76134, United States of America.
  • Wagner C; Chemical & Pharmaceutical Development, Merck Healthcare KGaA, The healthcare business of Merck KGaA, Darmstadt, Germany.
  • Vertzoni M; Department of Pharmacy, National and Kapodistrian University of Athens, Zografou, Greece.
  • Reppas C; Department of Pharmacy, National and Kapodistrian University of Athens, Zografou, Greece. Electronic address: reppas@pharm.uoa.gr.
J Pharm Sci ; 112(8): 2240-2248, 2023 08.
Article en En | MEDLINE | ID: mdl-36918113
ABSTRACT
The Biorelevant Gastrointestinal Transfer (BioGIT) system is a useful screening tool for assessing the impact of dose and/or formulation on early exposure after administration of immediate release or enabling drug products with a glass of water in the fasted state. The objective of this study was to investigate potential limitations. BioGIT experiments were performed with five low solubility active pharmaceutical ingredients with weakly alkaline characteristics mebendazole (tablet and chewable tablet), Compound E (aqueous solutions, three doses), pazopanib-HCl (Votrient™ tablet, crushed Votrient™ tablet and aqueous suspension), Compound B-diHCl (hard gelatin capsule, three doses) and Compound C (hard gelatin capsule containing nanosized drug and hard gelatin capsule containing micronized drug). For all formulation or dose comparisons the ratio of mean BioGIT AUC0-50 min values was not predictive of the ratio of mean plasma AUC0-60 min values which became available after completion of BioGIT experiments. BioGIT experimental conditions have not been designed to simulate the gastrointestinal drug transfer process after administration of chewable tablets or aqueous solutions, therefore, BioGIT may not be useful for the assessment of intraluminal performance early after administration of such drug products. Also, based on this study, BioGIT may not be useful in investigating the impact of dose and/or formulation on early exposure when the dose is not administered with a glass of water to fasted healthy individuals or when BioGIT data are highly variable. Finally, the rapid dissolution of nanocrystals after administration of low solubility weak bases may require adjustment of the pH in the gastric compartment of BioGIT to slightly higher pH values. Limitations identified in this study for the BioGIT system may be also relevant to other in vitro systems proposed for similar evaluations.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Tracto Gastrointestinal / Gelatina Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: J Pharm Sci Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Tracto Gastrointestinal / Gelatina Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: J Pharm Sci Año: 2023 Tipo del documento: Article